Efficacy of Bupivacain Local Infiltration for the Management of Pain During Cesarean Section
NCT ID: NCT05404490
Last Updated: 2025-08-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
202 participants
INTERVENTIONAL
2022-06-01
2022-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Wound Infiltration of Liposomal Bupivacaine v Plain Bupivacaine for Post-Op Pain Control in Elective Cesarean Delivery
NCT03353363
Bupivacaine Infiltration and Postoperative Pain
NCT04728308
Impact of Local Anesthetic Wound Infiltration on Postoperative Pain Following Cesarean Delivery
NCT02829944
Lidocaine Patch Versus Intravenous Lidocaine in Pain Relief After Cesarean Section
NCT04505644
Pharmacokinetics of BPV Following Bilateral US-guided TAP Block for C-section
NCT03006042
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bupivacaine
20 mL of bupivacaine 0.5% will be infiltrated. 10 mL will be infiltrated in the inferior border and 10 mL in the superior border of the subcutaneous cellular tissue.
Bupivacain
20 mL of bupivacaine 0.5% will be infiltrated. 10 mL will be infiltrated in the inferior border and 10 mL in the superior border of the subcutaneous cellular tissue.
Placebo
20 mL of Normal Saline Solution will be infiltrated. 10 mL will be infiltrated in the inferior border and 10 mL in the superior border of the subcutaneous cellular tissue.
Placebo
20 mL of Normal Saline Solution will be infiltrated. 10 mL will be infiltrated in the inferior border and 10 mL in the superior border of the subcutaneous cellular tissue.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bupivacain
20 mL of bupivacaine 0.5% will be infiltrated. 10 mL will be infiltrated in the inferior border and 10 mL in the superior border of the subcutaneous cellular tissue.
Placebo
20 mL of Normal Saline Solution will be infiltrated. 10 mL will be infiltrated in the inferior border and 10 mL in the superior border of the subcutaneous cellular tissue.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Elective cesarean section
* Transverse segmental caesarean section Pfannenstiel type
* Spinal anesthesia
* Maternal age 18 to 45 years
* Any gravaparity
* Patient ASA I or II
* Emergency cesarean section
* History of chronic or neuropathic pain
* Patient with cardiopulmonary disease
* Known allergies to the drugs used in the study
* Patient who does not wish to participate in the study
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Saint Thomas Hospital, Panama
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Osvaldo A. Reyes T.
Chair of the Research Department
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Saint Thomas H
Panama City, Provincia de Panamá, Panama
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-575
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.